Technical Analysis for SRPT - Sarepta Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Flat | Down | Down |
| Historical SRPT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Fell Below 200 DMA | Bearish | 0.00% | |
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -4.83% | |
| Bollinger Band Squeeze | Range Contraction | -4.83% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 12/01/2020
- Sector: Healthcare
- Industry: Biotechnology
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Biotechnology Biopharmaceutical Life Sciences Biology Infectious Diseases Rare Diseases Duchenne Muscular Dystrophy Therapeutic Gene Modulation Antisense RNA
Biotechnology Biopharmaceutical Life Sciences Biology Infectious Diseases Rare Diseases Duchenne Muscular Dystrophy Therapeutic Gene Modulation Antisense RNA
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 158.8 |
| 52 Week Low | 72.27 |
| Average Volume | 1,123,610 |
| 200-Day Moving Average | 114.35 |
| 50-Day Moving Average | 124.29 |
| 20-Day Moving Average | 120.75 |
| 10-Day Moving Average | 122.48 |
| Average True Range | 4.54 |
| ADX | 13.73 |
| +DI | 16.57 |
| -DI | 31.01 |
| Chandelier Exit (Long, 3 ATRs ) | 113.68 |
| Chandelier Exit (Short, 3 ATRs ) | 122.16 |
| Upper Bollinger Band | 128.13 |
| Lower Bollinger Band | 113.36 |
| Percent B (%b) | 0.03 |
| BandWidth | 12.23 |
| MACD Line | -0.38 |
| MACD Signal Line | 0.15 |
| MACD Histogram | -0.5332 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 125.79 | ||||
| Resistance 3 (R3) | 126.78 | 123.76 | 123.79 | ||
| Resistance 2 (R2) | 123.76 | 120.71 | 123.27 | 123.12 | |
| Resistance 1 (R1) | 118.78 | 118.82 | 117.27 | 117.79 | 122.46 |
| Pivot Point | 115.76 | 115.76 | 115.01 | 115.27 | 115.76 |
| Support 1 (S1) | 110.78 | 112.71 | 109.27 | 109.79 | 105.12 |
| Support 2 (S2) | 107.76 | 110.82 | 107.27 | 104.46 | |
| Support 3 (S3) | 102.78 | 107.76 | 103.79 | ||
| Support 4 (S4) | 101.79 |
